Merck.com - Research and Development News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from a Phase 2 study evaluating the safety, efficacy and therapeutic dose range of MK-7264 (formerly AF-219) for the treatment of chronic cough. The highest dose evaluated, 50 mg, reduced Awake Cough Frequency (coughs/hour), the primary endpoint, by 37 percent from baseline relative to placebo (p=0.003). The 50 mg dose also demonstrated a reduction in patient-reported cough severity.Language: Engl...
Source: Merck.com - Research and Development News - May 22, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK chronic cough MSD NYSE:MRK Source Type: news

Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Dateline City: KENILWORTH, N.J. Findings Presented at The International Liver Congress ™ 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously FailedKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 (SVR) results 12 weeks after completion of therapy (SVR12, considered virologic cure) fromC-SURGE, an ongoing, open label Phase 2 clinical trial evaluating MK-3682B [uprifosbuvir (MK-3682)2/...
Source: Merck.com - Research and Development News - April 22, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hepatitis C MSD NYSE:MRK Source Type: news

Merck Underscores Continued Commitment to Fighting Infectious Diseases With More than 25 Data Presentations at ECCMID 2017
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 25 scientific data presentations on the company ’s established and investigational infectious disease medicines at this year’s 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 22-25 in Vienna, Austria.Language: EnglishContact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-295-0928orInvestor:Teri Loxam, 908-740-1986orAmy ...
Source: Merck.com - Research and Development News - April 19, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ECCMID MSD NYSE:MRK Source Type: news

Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes
Dateline City: KENILWORTH, N.J.& NEW YORK Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA® (sitagliptin) or MetforminKENILWORTH, N.J.& NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S.Language: EnglishContact: Merck Media:Doris Li, (908) 246-5701orMerck Investor:Amy Klug, (908) 740-1898orKristen Drake, (908) 236-4223orPfizer Media:Steve Danehy, (212) 733-1538orPfizer Investor:Ryan Crowe, (212) 733-8160Ticker Slug:Ticker:MRK...
Source: Merck.com - Research and Development News - March 6, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK #Pfizer $MRK $PFE Januvia MSD NYSE:MRK Source Type: news

Merck ’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study
Dateline City: KENILWORTH, N.J. Letermovir Prophylaxis Associated with Lower All-Cause Mortality Through Week 24 Post-Transplant Company Plans to Submit New Drug Applications for Letermovir in U.S. and EU in 2017KENILWORTH, N.J.--(BUSINESS WIRE)--Merck& Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, today announced results of the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of an allogenei...
Source: Merck.com - Research and Development News - February 26, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Letermovir MSD NYSE:MRK Source Type: news

In First Phase 3 Trial, Merck ’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company ’s investigational inactivated varicella zoster virus vaccine (VZV) for the prevention of herpes zoster or HZ, also known as shingles, in immunocompromised patients.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orSkip Irvine, 267-305-0338orInvestors:Amy Klug, 908-740-1898orMichael DeCarbo, 908-740-1807Ticker Slug:Ticker:MRKExchange:NYSE @Merckread ...
Source: Merck.com - Research and Development News - February 24, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news

Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer ’s Disease to Stop for Lack of Efficacy
Dateline City: KENILWORTH, N.J. APECS Study in People with Prodromal Alzheimer ’s Disease to ContinueKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating verubecestat, an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), in people with mild-to-moderate Alzheimer ’s disease (AD).Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558Ian McCon...
Source: Merck.com - Research and Development News - February 14, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news

Merck ’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial
Dateline City: KENILWORTH, N.J. Data Presented at CROI Showed Doravirine Was Non-inferior to Ritonavir-boosted Darunavir in Treatment-na ïve Adults after 48 weeks of TreatmentKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI).Language: EnglishContact: MerckMedia:Doris Li, 908-246-5701Carmen de Gourville, 267-664-0146orInvestors:Teri...
Source: Merck.com - Research and Development News - February 14, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Doravirine HIV MSD NYSE:MRK Source Type: news

Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine
Dateline City: KENILWORTH, N.J. Results of First Phase 3 Trial Anticipated in Late 2017KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat, an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), for the potential treatment of Alzheimer ’s disease (AD).Language: EnglishContact: MerckMedia:Pam Eisele, 267-305-3558orIan McConnell, 908-740...
Source: Merck.com - Research and Development News - November 2, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK alzheimers NYSE:MRK verubecestat Source Type: news

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
Dateline City: KENILWORTH, N.J., and NEW YORK, N.Y.New Phase 3 Data Presented at the European Association for the Study of Diabetes Annual Meeting – Study Achieved Primary and All Key Secondary EndpointsKENILWORTH, N.J., and NEW YORK, N.Y. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint.Language: Englishread more (Source: Merck.com - Research and Development News)
Source: Merck.com - Research and Development News - September 15, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Merck Provides Update on Odanacatib Development Program
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it is discontinuing the development of odanacatib, Merck ’s investigational cathepsin K inhibitor for osteoporosis, and will not seek regulatory approval for its use.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Teri Loxam, 908-740-1986Ticker Slug:Ticker:MRKExchange:NYSEread more (Source: Merck.com - Research and Development News)
Source: Merck.com - Research and Development News - September 2, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK NYSE:MRK odanacatib Source Type: news

Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine
Dateline City: KENILWORTH, N.J. Marketing Authorization Application to the European Medicines Agency Currently Under ReviewKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MK-1293, an investigational follow-on biologic1 insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes, which is being developed by Merck with partial funding from Samsung Bioepis.Language: Engl...
Source: Merck.com - Research and Development News - August 5, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Glargine MSD Source Type: news

Data for Merck's Investigational Once-Daily Formulation of ISENTRESS ® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Resulted in Non-Inferior Efficacy and Safety to a Regimen Containing the Approved Twice-Daily Formulation < /p > < p > EMA Accepts File A...
Source: Merck.com - Research and Development News - July 22, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK HIV ISENTRESS MSD NYSE:MRK Source Type: news

Results of Phase 2 Study of Merck ’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections < /p > < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a tar...
Source: Merck.com - Research and Development News - June 20, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ASM MSD NYSE:MRK Source Type: news

Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
Dateline City: KENILWORTH, N.J. Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company’s investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), in patients with complicated urinary tract infections, met its prima...
Source: Merck.com - Research and Development News - June 20, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ASM MSD NYSE:MRK Source Type: news